MAPK1 and breast cancer: Further analysis showed that high ERK2 expression levels were highly correlated with decreased overall survival of patients with TNBC and luminal A breast cancer (Figure S4B), suggesting that ERK2 overexpression is correlated with a poorer prognosis of subtypes of breast cancer.